Literature DB >> 11359788

Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways.

S Descamps1, R A Toillon, E Adriaenssens, V Pawlowski, S M Cool, V Nurcombe, X Le Bourhis, B Boilly, J P Peyrat, H Hondermarck.   

Abstract

We show here that the neurotrophin nerve growth factor (NGF), which has been shown to be a mitogen for breast cancer cells, also stimulates cell survival through a distinct signaling pathway. Breast cancer cell lines (MCF-7, T47-D, BT-20, and MDA-MB-231) were found to express both types of NGF receptors: p140(trkA) and p75(NTR). The two other tyrosine kinase receptors for neurotrophins, TrkB and TrkC, were not expressed. The mitogenic effect of NGF on breast cancer cells required the tyrosine kinase activity of p140(trkA) as well as the mitogen-activated protein kinase (MAPK) cascade, but was independent of p75(NTR). In contrast, the anti-apoptotic effect of NGF (studied using the ceramide analogue C2) required p75(NTR) as well as the activation of the transcription factor NF-kB, but neither p140(trkA) nor MAPK was necessary. Other neurotrophins (BDNF, NT-3, NT-4/5) also induced cell survival, although not proliferation, emphasizing the importance of p75(NTR) in NGF-mediated survival. Both the pharmacological NF-kappaB inhibitor SN50, and cell transfection with IkBm, resulted in a diminution of NGF anti-apoptotic effect. These data show that two distinct signaling pathways are required for NGF activity and confirm the roles played by p75(NTR) and NF-kappaB in the activation of the survival pathway in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359788     DOI: 10.1074/jbc.M010499200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  Functional interaction between p75NTR and TrkA: the endocytic trafficking of p75NTR is driven by TrkA and regulates TrkA-mediated signalling.

Authors:  Lorena Perrone; Simona Paladino; Marialuisa Mazzone; Lucio Nitsch; Massimo Gulisano; Chiara Zurzolo
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

3.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

4.  Nerve growth factor: the dark side of the icon.

Authors:  Hubert Hondermarck
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 5.  Cardiovascular actions of neurotrophins.

Authors:  Andrea Caporali; Costanza Emanueli
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 6.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

Review 7.  Perineural growth in head and neck squamous cell carcinoma: a review.

Authors:  Joseph Roh; Thomas Muelleman; Ossama Tawfik; Sufi M Thomas
Journal:  Oral Oncol       Date:  2014-10-25       Impact factor: 5.337

Review 8.  NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

Authors:  Ralph A Bradshaw; Jay Pundavela; Jordane Biarc; Robert J Chalkley; A L Burlingame; Hubert Hondermarck
Journal:  Adv Biol Regul       Date:  2014-11-20

9.  Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis.

Authors:  Siba P Raychaudhuri; Wen-Yue Jiang; Smriti K Raychaudhuri
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 10.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.